NTpro-BNP levels in patients with primary hyperaldosteronism and autonomous cortisol co-secretion.

ACTH Conn´s syndrome aldosterone cardiac comorbidity dexamethasone suppression test hypercortisolism left ventricular hypertrophy pro-BNP renin

Journal

European journal of endocrinology
ISSN: 1479-683X
Titre abrégé: Eur J Endocrinol
Pays: England
ID NLM: 9423848

Informations de publication

Date de publication:
29 Sep 2024
Historique:
received: 23 04 2024
revised: 24 07 2024
accepted: 26 09 2024
medline: 30 9 2024
pubmed: 30 9 2024
entrez: 29 9 2024
Statut: aheadofprint

Résumé

Patients with primary aldosteronism (PA) have higher cardiac comorbidities including more pronounced left ventricular hypertrophy than patients with essential hypertension. Autonomous cortisol co-secretion (ACS) is a common subtype in PA associated with a worse metabolic profile. ACS may affect myocardial parameters and result in a worse cardiac outcome compared to patients with PA and without ACS. 367 patients with PA undergoing 1mg dexamethasone suppression test (DST) and echocardiography at baseline from two centers of the German Conn´s Registry were included. Follow-up for up to 3.8yrs was available in 192 patients. Patients with PA and ACS had higher NTpro-BNP levels at baseline compared to patients with PA without ACS (114vs75.6pg/ml,p=0.02), but showed no difference in echocardiography values. NTpro-BNP levels showed a significant positive correlation (r=0.141,p=0.011) with cortisol levels after DST at baseline. In response to therapy of PA, NTpro-BNP levels decreased, but remained significantly higher in patients with ACS compared to patients without ACS. At follow-up, left ventricle end diastolic dimension (LVEDD) decreased significantly only in patients without ACS. Left atrial diameter (LAD) decreased significantly in patients without ACS and in female patients with ACS but not in male patients. Left ventricular mass index (LVMI) significantly improved in female patients without ACS but remained unchanged in female patients with ACS as well as in male patients at follow-up. In patients with PA, concomitant ACS is associated with a worse cardiac profile and only partial recovery even years after initiation of targeted PA therapy.

Identifiants

pubmed: 39343731
pii: 7792572
doi: 10.1093/ejendo/lvae119
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

Auteurs

Anna Hirsch (A)

Endocrinology in Charlottenburg, 10627 Berlin, Germany.
Clinical Endocrinology CCM, Charité Universitätsmedizin Berlin, 10117 Berlin, Germany.

Christian Adolf (C)

Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, München, Germany.

Isabel Stüfchen (I)

Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, München, Germany.

Felix Beuschlein (F)

Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, München, Germany.
Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, UniversitätsSpital Zürich (USZ) und Universität Zürich (UZH), Zurich, Switzerland.
The LOOP Zurich - Medical Research Center, Zurich, Switzerland.

Denise Brüdgam (D)

Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, München, Germany.

Martin Bidlingmaier (M)

Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, München, Germany.

Martin Reincke (M)

Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, München, Germany.

Marcus Quinkler (M)

Endocrinology in Charlottenburg, 10627 Berlin, Germany.

Classifications MeSH